GGrantIndex
← Leaderboards

Jieli Chen

Henry Ford Health System

$7,266,447
Attributed
$7,916,386
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.5M · FY200519
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19

Funding mix

By agency

NIH$7,916,386 · 8

By mechanism

R01$7,316,514 · 6
R41$599,872 · 2

Top collaborators

Most similar at Henry Ford Health System

Same institution · by research overlap

Others in their field

Top investigators on “Base

Research focus

BaseStrokeNeurologicIschemic StrokeNeurorestorationBrainDesignMediatingMorbidity - Disease RateStroke TherapyFunctional OutcomesPathway InteractionsNervous System PhysiologyCerebrumDisabilityRecovery Of FunctionBlood VesselsSerumAngiogenesisTherapeutic EffectClinically RelevantRecoveryDiabetes MellitusAdult

Grant awards (25)

Diabetic stroke cardiac dysfunction; treatment with CD133+Exosomes$461,609
R01 · FY2019 · HL · contact PI
Investigation of D-4F effects of neurovascular remodeling after diabetic stroke$434,174
R01 · FY2019 · NS
Diabetic stroke cardiac dysfunction; treatment with CD133+Exosomes$461,609
R01 · FY2018 · HL · contact PI
Investigation of D-4F effects of neurovascular remodeling after diabetic stroke$434,174
R01 · FY2018 · NS
MiR-126/ABCA1 mediates exosome induced neurorestorative effects after stroke in T2DM mice$329,219
R01 · FY2018 · NS · contact PI
Neurorestorative therapy of stroke with HUCBC in type two diabetic mice$324,844
R01 · FY2018 · NS · contact PI
Investigation of D-4F effects of neurovascular remodeling after diabetic stroke$431,530
R01 · FY2017 · NS
MiR-126/ABCA1 mediates exosome induced neurorestorative effects after stroke in T2DM mice$328,125
R01 · FY2017 · NS · contact PI
Neurorestorative therapy of stroke with HUCBC in type two diabetic mice$324,844
R01 · FY2017 · NS · contact PI
MiR-126/ABCA1 mediates exosome induced neurorestorative effects after stroke in T2DM mice$327,031
R01 · FY2016 · NS · contact PI
Neurorestorative therapy of stroke with HUCBC in type two diabetic mice$324,844
R01 · FY2016 · NS · contact PI
Neurorestorative therapy of stroke with HUCBC in type two diabetic mice$324,844
R01 · FY2015 · NS · contact PI
Neurorestorative therapy of stroke with HUCBC in type two diabetic mice$324,844
R01 · FY2014 · NS · contact PI
Neurorestorative therapy of stroke with HUCBC in T2DM rats$211,473
R41 · FY2014 · NS · contact PI
Neurorestorative therapy of stroke with agents that increase HDL$270,068
R01 · FY2013 · AG · contact PI
Neurorestorative therapy of stroke with HUCBC in T2DM rats$211,473
R41 · FY2013 · NS · contact PI
Neurorestorative therapy of stroke with agents that increase HDL$285,786
R01 · FY2012 · AG · contact PI
Neurorestorative therapy of stroke with agents that increase HDL$285,786
R01 · FY2011 · AG · contact PI
Neurorestorative therapy of stroke with agents that increase HDL$297,322
R01 · FY2010 · AG · contact PI
Neuroprotective therapy of stroke with HUCNC and simvastatin$176,926
R41 · FY2010 · NS · contact PI
Neurorestorative therapy of stroke with agents that increase HDL$300,325
R01 · FY2009 · AG · contact PI
Neurorestorative Therapy of Stroke with Statins$252,596
R01 · FY2007 · NS · contact PI
Neurorestorative Therapy of Stroke with Statins$260,140
R01 · FY2006 · NS · contact PI
Neurorestorative Therapy of Stroke with Statins$266,400
R01 · FY2005 · NS
Neurorestorative Therapy of Stroke with Statins$266,400
R01 · FY2004 · NS